journal article·2025-01-14Open access

Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases

Nargish Parvin, Sang Woo Joo, Tapas K. Mandal

Abstract

Autoimmune diseases present complex therapeutic challenges due to their chronic nature, systemic impact, and requirement for precise immunomodulation to avoid adverse side effects. Recent advancements in biodegradable and stimuli-responsive nanomaterials have opened new avenues for targeted drug delivery systems capable of addressing these challenges. This review provides a comprehensive analysis of state-of-the-art biodegradable nanocarriers such as polymeric nanoparticles, liposomes, and hydrogels engineered for targeted delivery in autoimmune therapies. These nanomaterials are designed to degrade safely in the body while releasing therapeutic agents in response to specific stimuli, including pH, temperature, redox conditions, and enzymatic activity. By achieving localized and controlled release of anti-inflammatory and immunosuppressive agents, these systems minimize systemic toxicity and enhance therapeutic efficacy. We discuss the underlying mechanisms of stimuli-responsive nanomaterials, recent applications in treating diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease, and the design considerations essential for clinical translation. Additionally, we address current challenges, including biocompatibility, scalability, and regulatory hurdles, as well as future directions for integrating advanced nanotechnology with personalized medicine in autoimmune treatment. This review highlights the transformative potential of biodegradable and stimuli-responsive nanomaterials, presenting them as a promising strategy to advance precision medicine and improve patient outcomes in autoimmune disease management.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Mechanical Engineering, School of Basic Science, Yeungnam University, Gyeongsan 38541, Republic of Korea

Funding

National Research Foundation of Korea (NRF)

References (100+)

Show source-provided references
1. Nautiyal, G., Sharma, I., Pandey, P., and Sharma, S.K. (2024). Autoimmune Diseases: Recent Insights on Epidemiology, Pathogenesis, and Prevalence Rate. Artificial Intelligence and Autoimmune Diseases: Applications in the Diagnosis, Prognosis, and Therapeutics, Springer.10.1007/978-981-99-9029-0_2 ↗
2. Kumar, S., Kaushik, D., and Sharma, S.K. (2024). Autoimmune Disorders: Types, Symptoms, and Risk Factors. Artificial Intelligence and Autoimmune Diseases: Applications in the Diagnosis, Prognosis, and Therapeutics, Springer.10.1007/978-981-99-9029-0_1 ↗
3. Yasmeen, F., Pirzada, R.H., Ahmad, B., Choi, B., and Choi, S. (2024). Understanding Autoimmunity: Mechanisms, Predisposing Factors, and Cytokine Therapies. Int. J. Mol. Sci., 25.10.3390/ijms25147666 ↗
4. Dysbiosis and the Immune System10.1038/nri.2017.7 ↗
5. Inflammation and Rheumatoid Arthritis10.1007/s13105-012-0216-5 ↗
6. Ananthakrishnan, A.N., and Xavier, R.J. (2020). Gastrointestinal Diseases. Hunter’s Tropical Medicine and Emerging Infectious Diseases, Elsevier.10.1016/B978-0-323-55512-8.00003-X ↗
7. Systemic Treatment-Induced Gastrointestinal Toxicity: Incidence, Clinical Presentation and Management
8. Nanomedicine–Nanoscale Drugs and Delivery Systems10.1166/jnn.2010.3617 ↗
9. Placha, D., and Jampilek, J. (2021). Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems. Pharmaceutics, 13.10.3390/pharmaceutics13010064 ↗
10. “Smart” Stimuli-Responsive Biomaterials Revolutionizing the Theranostic Landscape of Inflammatory Arthritis10.1016/j.mtchem.2024.102178 ↗
11. PH-Responsive Biocompatible Fluorescent Core-Shell Nanogel for Intracellular Imaging and Control Drug Release10.1002/ppsc.202100110 ↗
12. Highly Fluorescent Doped Fe3O4@C Nanoparticles Cross the Blood–Brain Barrier: Help in Brain Imaging and Blocking the Life Cycle of Mosquitoes10.1007/s10876-020-01938-w ↗
13. Pham, S.H., Choi, Y., and Choi, J. (2020). Stimuli-Responsive Nanomaterials for Application in Antitumor Therapy and Drug Delivery. Pharmaceutics, 12.10.3390/pharmaceutics12070630 ↗
14. Das, S.S., Bharadwaj, P., Bilal, M., Barani, M., Rahdar, A., Taboada, P., Bungau, S., and Kyzas, G.Z. (2020). Stimuli-Responsive Polymeric Nanocarriers for Drug Delivery, Imaging, and Theragnosis. Polymers, 12.10.3390/polym12061397 ↗
15. Kondo, N., Kuroda, T., and Kobayashi, D. (2021). Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis. Int. J. Mol. Sci., 22.10.3390/ijms222010922 ↗
16. The Interaction between Epstein–Barr Virus and Multiple Sclerosis Genetic Risk Loci: Insights into Disease Pathogenesis and Therapeutic Opportunities10.1002/cti2.1454 ↗
17. Abdominal Pain in Inflammatory Bowel Disease: An Evidence-Based, Multidisciplinary Review10.1093/crocol/otad055 ↗
18. Cascade of Immune Mechanism and Consequences of Inflammatory Disorders10.1016/j.phymed.2021.153712 ↗
19. Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases10.1016/j.cell.2020.03.007 ↗
20. Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?10.1210/endrev/bnad016 ↗
21. Fenton, K.A., and Pedersen, H.L. (2023). Advanced Methods and Novel Biomarkers in Autoimmune Diseases—A Review of the Recent Years Progress in Systemic Lupus Erythematosus. Front. Med., 10.10.3389/fmed.2023.1183535 ↗
22. Inflammasome Molecular Insights in Autoimmune Diseases10.3390/cimb46040220 ↗
23. Nanotechnology-Based Drug Delivery Systems for the Treatment of Cervical Cancer: A Comprehensive Review10.2174/1573413719666230413084140 ↗
24. Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine10.1155/2019/3702518 ↗
25. An Overview of Nanoparticles in Drug Delivery: Properties and Applications
26. Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., and Alcudia, A. (2020). Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials, 10.10.3390/nano10071403 ↗
27. Liu, P., Chen, G., and Zhang, J. (2022). A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules, 27.10.3390/molecules27041372 ↗
28. Nanotechnology’s Frontier in Combatting Infectious and Inflammatory Diseases: Prevention and Treatment10.1038/s41392-024-01745-z ↗
29. Nanomedicines for the Treatment of Rheumatoid Arthritis: State of Art and Potential Therapeutic Strategies10.1016/j.apsb.2021.03.013 ↗
30. Nano-Based Approaches for the Treatment of Neuro-Immunological Disorders: A Special Emphasis on Multiple Sclerosis10.1186/s11671-024-04135-0 ↗
31. Barani, M., Rahdar, A., Sargazi, S., Amiri, M.S., Sharma, P.K., and Bhalla, N. (2021). Nanotechnology for Inflammatory Bowel Disease Management: Detection, Imaging and Treatment. Sens. Bio-Sens. Res., 32.10.1016/j.sbsr.2021.100417 ↗
32. Therapeutic Applications of Nanomedicine in Autoimmune Diseases: From Immunosuppression to Tolerance Induction10.1016/j.nano.2014.12.003 ↗
33. Smart PH-Responsive Nanomedicines for Disease Therapy10.1007/s40005-022-00573-z ↗
34. Sivadasan, D., Sultan, M.H., Madkhali, O., Almoshari, Y., and Thangavel, N. (2021). Polymeric Lipid Hybrid Nanoparticles (PLNs) as Emerging Drug Delivery Platform—A Comprehensive Review of Their Properties, Preparation Methods, and Therapeutic Applications. Pharmaceutics, 13.10.3390/pharmaceutics13081291 ↗
35. Thomas, R.G., Surendran, S.P., and Jeong, Y.Y. (2020). Tumor Microenvironment-Stimuli Responsive Nanoparticles for Anticancer Therapy. Front. Mol. Biosci., 7.10.3389/fmolb.2020.610533 ↗
36. Poly(N-isopropylacrylamide)-Based Polymers: Recent Overview for the Development of Temperature-Responsive Drug Delivery and Biomedical Applications10.1002/macp.202300157 ↗
37. Research Progress of Disulfide Bond Based Tumor Microenvironment Targeted Drug Delivery System10.2147/IJN.S471734 ↗
38. Ren, S., Xu, Y., Dong, X., Mu, Q., Chen, X., Yu, Y., and Su, G. (2024). Nanotechnology-Empowered Combination Therapy for Rheumatoid Arthritis: Principles, Strategies, and Challenges. J. Nanobiotechnol., 22.10.1186/s12951-024-02670-7 ↗
39. Li, M., Zhao, G., Su, W.-K., and Shuai, Q. (2020). Enzyme-Responsive Nanoparticles for Anti-Tumor Drug Delivery. Front. Chem., 8.10.3389/fchem.2020.00647 ↗
40. Lôbo, G.C.N.B., Paiva, K.L.R., Silva, A.L.G., Simões, M.M., Radicchi, M.A., and Báo, S.N. (2021). Nanocarriers Used in Drug Delivery to Enhance Immune System in Cancer Therapy. Pharmaceutics, 13.10.3390/pharmaceutics13081167 ↗
41. Cao, Y., Dong, X., and Chen, X. (2022). Polymer-Modified Liposomes for Drug Delivery: From Fundamentals to Applications. Pharmaceutics, 14.10.3390/pharmaceutics14040778 ↗
42. A Comparative Investigation of Release Kinetics of Paclitaxel from Natural Protein and Macromolecular Nanocarriers in Nanoscale Drug Delivery Systems10.1016/j.jciso.2024.100120 ↗
43. The Drug Release of PLGA-Based Nanoparticles and Their Application in Treatment of Gastrointestinal Cancers10.1016/j.heliyon.2024.e38165 ↗
44. Enzymatically Activatable Polymers for Disease Diagnosis and Treatment10.1002/adma.202306358 ↗
45. Poly(Lactic-Co-Glycolic) Acid-Controlled-Release Systems: Experimental and Modeling Insights10.1615/CritRevTherDrugCarrierSyst.2013006475 ↗
46. Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release10.1021/acs.chemrev.5b00346 ↗
47. Current Approaches in Lipid-Based Nanocarriers for Oral Drug Delivery10.1007/s13346-021-00908-7 ↗
48. Liao, S., Jia, S., Yue, Y., Zeng, H., Lin, J., and Liu, P. (2024). Advancements in PH-Responsive Nanoparticles for Osteoarthritis Treatment: Opportunities and Challenges. Front. Bioeng. Biotechnol., 12.10.3389/fbioe.2024.1426794 ↗
49. Gupta, A., Lee, J., Ghosh, T., Nguyen, V.Q., Dey, A., Yoon, B., Um, W., and Park, J.H. (2022). Polymeric Hydrogels for Controlled Drug Delivery to Treat Arthritis. Pharmaceutics, 14.10.3390/pharmaceutics14030540 ↗
50. Functionalized Liposomes for Targeted Breast Cancer Drug Delivery
51. Guo, X., Zuo, X., Zhou, Z., Gu, Y., Zheng, H., Wang, X., Wang, G., Xu, C., and Wang, F. (2023). PLGA-Based Micro/Nanoparticles: An Overview of Their Applications in Respiratory Diseases. Int. J. Mol. Sci., 24.10.3390/ijms24054333 ↗
52. Sawan, S., Kumari, A., Majie, A., Ghosh, A., Karmakar, V., Kumari, N., Ghosh, S., and Gorain, B. (2025). SiRNA-Based Nanotherapeutic Approaches for Targeted Delivery in Rheumatoid Arthritis. Biomater. Adv., 168.10.1016/j.bioadv.2024.214120 ↗
53. Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier10.1021/acsnano.3c10674 ↗
54. Chountoulesi, M., and Demetzos, C. (2020). Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System. Brain Sci., 10.10.3390/brainsci10060338 ↗
55. Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development10.1021/acsmaterialsau.3c00032 ↗
56. Li, H., Yang, Y.-G., and Sun, T. (2022). Nanoparticle-Based Drug Delivery Systems for Induction of Tolerance and Treatment of Autoimmune Diseases. Front. Bioeng. Biotechnol., 10.10.3389/fbioe.2022.889291 ↗
57. Exploring Potential of Exosomes Drug Delivery System in the Treatment of Cancer: Advances and Prospective10.1016/j.medidd.2023.100163 ↗
58. A Complex Molecular Landscape to Drug Delivery Concept for Achieving Precise Therapy in Psoriasis10.1016/j.medidd.2024.100183 ↗
59. Recent Advances in Nanoparticle-Based Drug Delivery Systems for Rheumatoid Arthritis Treatment10.1039/D2NA00229A ↗
60. Nanotechnology in Inflammation: Cutting-Edge Advances in Diagnostics, Therapeutics and Theranostics10.7150/thno.91394 ↗
61. Recent Advances on Drug Delivery Nanoplatforms for the Treatment of Autoimmune Inflammatory Diseases10.1039/D2MA00814A ↗
62. Li, X., Lu, C., Yang, Y., Yu, C., and Rao, Y. (2020). Site-Specific Targeted Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease. Biomed. Pharmacother., 129.10.1016/j.biopha.2020.110486 ↗
63. Liposomes and Extracellular Vesicles as Drug Delivery Systems: A Comparison of Composition, Pharmacokinetics, and Functionalization10.1002/adhm.202100639 ↗
64. A Review of Design and Fabrication Methods for Nanoparticle Network Hydrogels for Biomedical, Environmental, and Industrial Applications10.1002/adfm.202102355 ↗
65. Therapeutic Effect of 5-ASA and Hesperidin-Loaded Chitosan/Eudragit® S100 Nanoparticles as a PH-Sensitive Carrier for Local Targeted Drug Delivery in a Rat Model of Ulcerative Colitis10.1016/j.ijpharm.2024.123838 ↗
66. Polymeric Particle-Based Therapies for Acute Inflammatory Diseases10.1038/s41578-022-00458-5 ↗
67. Zhang, W., Michalowski, C.B., and Beloqui, A. (2021). Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment. Front. Bioeng. Biotechnol., 9.10.3389/fbioe.2021.675194 ↗
68. Multifunctional Hydrogels Based on Chitosan, Hyaluronic Acid and Other Biological Macromolecules for the Treatment of Inflammatory Bowel Disease: A Review10.1016/j.ijbiomac.2022.12.032 ↗
69. Lipidoid-SiRNA Nanoparticle-Mediated IL-1β Gene Silencing for Systemic Arthritis Therapy in a Mouse Model10.1016/j.ymthe.2019.05.002 ↗
70. Nanoparticles for Oral Delivery: Targeted Therapy for Inflammatory Bowel Disease10.1039/D2TB01190E ↗
71. Multifunctional Folate Receptor-Targeting and PH-Responsive Nanocarriers Loaded with Methotrexate for Treatment of Rheumatoid Arthritis10.2147/IJN.S140992 ↗
72. Glatiramer Acetate in Situ Forming Gel, a New Approach for Multiple Sclerosis Treatment10.1007/s40199-024-00532-z ↗
73. Tang, S., Wang, W., Wang, Y., Gao, Y., Dai, K., Zhang, W., Wu, X., Yuan, X., Jin, C., and Zan, X. (2024). Sustained Release of 5-Aminosalicylic Acid from Azoreductase-Responsive Polymeric Prodrugs for Prolonged Colon-Targeted Colitis Therapy. J. Nanobiotechnol., 22.10.1186/s12951-024-02724-w ↗
74. Rajes, K., Walker, K., Hadam, S., Zabihi, F., Rancan, F., Vogt, A., and Haag, R. (2020). Redox-Responsive Nanocarrier for Controlled Release of Drugs in Inflammatory Skin Diseases. Pharmaceutics, 13.10.3390/pharmaceutics13010037 ↗
75. Clinical Translation of Nanomedicines: Challenges, Opportunities, and Keys10.1016/j.addr.2021.114083 ↗
76. Aljabali, A.A., Obeid, M.A., Bashatwah, R.M., Serrano-Aroca, Á., Mishra, V., Mishra, Y., El-Tanani, M., Hromić-Jahjefendić, A., Kapoor, D.N., and Goyal, R. (2023). Nanomaterials and Their Impact on the Immune System. Int. J. Mol. Sci., 24.10.3390/ijms24032008 ↗
77. Komal Poly(Lactic-Co-Glycolic) Acid (PLGA) Nanoparticles and Transdermal Drug Delivery: An Overview10.2174/0113816128275385231027054743 ↗
78. Pondman, K., Le Gac, S., and Kishore, U. (2023). Nanoparticle-Induced Immune Response: Health Risk versus Treatment Opportunity?. Immunobiology, 228.10.1016/j.imbio.2022.152317 ↗
79. Nanoparticles-induced Potential Toxicity on Human Health: Applications, Toxicity Mechanisms, and Evaluation Models10.1002/mco2.327 ↗
80. Hofer, S., Hofstätter, N., Punz, B., Hasenkopf, I., Johnson, L., and Himly, M. (2022). Immunotoxicity of Nanomaterials in Health and Disease: Current Challenges and Emerging Approaches for Identifying Immune Modifiers in Susceptible Populations. WIREs Nanomed. Nanobiotechnol., 14.10.1002/wnan.1804 ↗
81. Ly, P.-D., Ly, K.-N., Phan, H.-L., Nguyen, H.H.T., Duong, V.-A., and Nguyen, H.V. (2024). Recent Advances in Surface Decoration of Nanoparticles in Drug Delivery. Front. Nanotechnol., 6.10.3389/fnano.2024.1456939 ↗
82. Scale-up Polymeric-Based Nanoparticles Drug Delivery Systems: Development and Challenges10.1016/j.onano.2022.100048 ↗
83. Microfluidic Devices: A Tool for Nanoparticle Synthesis and Performance Evaluation10.1021/acsnano.3c01117 ↗
84. Engineering Precision Nanoparticles for Drug Delivery10.1038/s41573-020-0090-8 ↗
85. Synthesis of Green Nanoparticles for Energy, Biomedical, Environmental, Agricultural, and Food Applications: A Review10.1007/s10311-023-01682-3 ↗
86. The Regulation of Nanomaterials and Nanomedicines for Clinical Application: Current and Future Perspectives10.1039/D0BM00558D ↗
87. Microfluidic Devices for Precision Nanoparticle Production10.3390/micro3040058 ↗
88. Modelling the Synthesis of Nanoparticles in Continuous Microreactors: The Role of Diffusion and Residence Time Distribution on Nanoparticle Characteristics10.1016/j.cej.2018.03.167 ↗
89. Eco-Friendly Greener Synthesis of Nanoparticles10.34172/apb.2020.067 ↗
90. Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., and Wu, J. (2022). Engineering Nano-Drug Biointerface to Overcome Biological Barriers toward Precision Drug Delivery. J. Nanobiotechnol., 20.10.1186/s12951-022-01605-4 ↗
91. Current Hurdles to the Translation of Nanomedicines from Bench to the Clinic10.1007/s13346-021-01024-2 ↗
92. Regulatory Challenges of Nanomedicines and Their Follow-on Versions: A Generic or Similar Approach?10.1016/j.addr.2018.06.024 ↗
93. Kumarasamy, R.V., Natarajan, P.M., Umapathy, V.R., Roy, J.R., Mironescu, M., and Palanisamy, C.P. (2024). Clinical Applications and Therapeutic Potentials of Advanced Nanoparticles: A Comprehensive Review on Completed Human Clinical Trials. Front. Nanotechnol., 6.10.3389/fnano.2024.1479993 ↗
94. A Review of Physical, Chemical and Biological Synthesis Methods of Bimetallic Nanoparticles and Applications in Sensing, Water Treatment, Biomedicine, Catalysis and Hydrogen Storage10.1016/j.cis.2023.103010 ↗
95. Review on Fate, Transport, Toxicity and Health Risk of Nanoparticles in Natural Ecosystems: Emerging Challenges in the Modern Age and Solutions toward a Sustainable Environment10.1016/j.scitotenv.2023.169331 ↗
96. Liu, J., Liu, Z., Pang, Y., and Zhou, H. (2022). The Interaction between Nanoparticles and Immune System: Application in the Treatment of Inflammatory Diseases. J. Nanobiotechnol., 20.10.1186/s12951-022-01343-7 ↗
97. Wreh, E. (2023). Premarket Approval (PMA). Medical Device Regulation, Elsevier.10.1016/B978-0-323-95354-2.00016-5 ↗
98. Regulatory Landscape of Nanotechnology and Nanoplastics from a Global Perspective10.1016/j.yrtph.2021.104885 ↗
99. Ahmed, T. (2022). Organ-on-a-Chip Microengineering for Bio-Mimicking Disease Models and Revolutionizing Drug Discovery. Biosens. Bioelectron. X, 11.10.1016/j.biosx.2022.100194 ↗
100. Toward an International Standardisation Roadmap for Nanomedicine10.1007/s13346-024-01646-2 ↗